Articles and Blogs

On February 3, 2026, after years of false starts, federal regulation of pharmacy benefit managers (“PBMs”) became reality when the Consolidated Appropriations Act, 2026 (the “Act”) was signed into law by President Trump. For the first time, the Act imposes federal requirements on PBMs related to compensation, transparency, reporting and other matters to be... READ MORE

In the latest example of enforcement action against pharmacy benefit managers (“PBMs”), Michigan Attorney General Dana Nessel recently filed an antitrust lawsuit in federal court against Express Scripts, Inc. and Prime Therapeutics LLC, alleging the two PBMs engaged in an unlawful agreement to suppress pharmacy reimbursement rates and harm competition (the “Complaint”). The Complaint,... READ MORE

On January 14, the Federal Trade Commission (“FTC”) published its Second Interim Staff Report (“Report”) on pharmacy benefit managers (“PBMs”), focusing on PBM pricing practices for specialty generic drugs. The Report described significant markups of cancer, HIV and other chronic condition specialty drugs and high reimbursement rates paid by Caremark Rx, Express Scripts and... READ MORE

House Democrats Unveil Single-Payor Legislation House Democrats introduced sweeping “Medicare for All” legislation, providing the most detailed plan to overhaul the current health care system by enrolling all U.S. residents in a single-payor, government-run health plan. It would cover a more expansive set of benefits than the current Medicare program and restructure payment for... READ MORE